BNTX

SEC source: 0002123975-26-000035 · wk-form4_1791578831.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

SEC source: 0002123975-26-000035 · wk-form4_1791578831.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 36,209

SEC source: 0002123975-26-000033 · wk-form4_1791407643.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 63,209

SEC source: 0002123975-26-000031 · wk-form4_1791320345.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 87,209

SEC source: 0002123975-26-000031 · wk-form4_1791320345.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,209

SEC source: 0002123975-26-000029 · wk-form4_1790972861.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 180,209

SEC source: 0002123975-26-000029 · wk-form4_1790972861.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 197,209

SEC source: 0002123975-26-000027 · wk-form4_1790800195.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 214,209

SEC source: 0002123975-26-000027 · wk-form4_1790800195.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 246,209

SEC source: 0002123975-26-000025 · wk-form4_1790630190.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 280,209

SEC source: 0002123975-26-000025 · wk-form4_1790630190.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 314,209

SEC source: 0002123975-26-000023 · wk-form4_1790281568.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 341,209

SEC source: 0002123975-26-000023 · wk-form4_1790281568.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 380,209

SEC source: 0002123975-26-000021 · wk-form4_1790111057.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 410,209

SEC source: 0002123975-26-000021 · wk-form4_1790111057.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 456,209

SEC source: 0002123975-26-000019 · wk-form4_1789764092.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 489,209

SEC source: 0002123975-26-000019 · wk-form4_1789764092.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 519,209

SEC source: 0002123975-26-000017 · wk-form4_1789591576.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 553,209

SEC source: 0002123975-26-000017 · wk-form4_1789591576.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 568,209

SEC source: 0002123975-26-000015 · wk-form4_1789419036.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 602,209

SEC source: 0002123975-26-000015 · wk-form4_1789419036.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 643,209

SEC source: 0002123975-26-000013 · wk-form4_1789161500.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 688,209

SEC source: 0002123975-26-000011 · wk-form4_1788989388.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 708,709

SEC source: 0002123975-26-000011 · wk-form4_1788989388.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 744,709

SEC source: 0002123975-26-000008 · wk-form4_1788898236.xml · nonDerivative · entry 2

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 781,709

SEC source: 0002123975-26-000008 · wk-form4_1788898236.xml · nonDerivative · entry 1

Sahin Ugur · CIK 0002123975 · Chief Executive Officer · 10% owner

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 813,209

SEC source: 0002123980-26-000005 · wk-form4_1778702941.xml · derivative · entry 2

Zapata Gomez Ramon · CIK 0002123980 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,103

Underlying: Ordinary Shares · 15,103 shares

Expires 2036-05-12

F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC source: 0002123980-26-000005 · wk-form4_1778702941.xml · derivative · entry 1

Zapata Gomez Ramon · CIK 0002123980 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,879

Underlying: Ordinary Shares · 18,879 shares

Expires 2036-05-12

F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

SEC source: 0002123964-26-000006 · wk-form4_1778702864.xml · derivative · entry 2

Ryan James Timothy Patrick · CIK 0002123964 · See remarks.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,069

Underlying: Ordinary Shares · 10,069 shares

Expires 2036-05-12

F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC source: 0002123964-26-000006 · wk-form4_1778702864.xml · derivative · entry 1

Ryan James Timothy Patrick · CIK 0002123964 · See remarks.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,586

Underlying: Ordinary Shares · 12,586 shares

Expires 2036-05-12

F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

SEC source: 0001955589-26-000004 · wk-form4_1778702747.xml · derivative · entry 2

Poetting Sierk · CIK 0001955589 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,069

Underlying: Ordinary Shares · 10,069 shares

Expires 2036-05-12

F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC source: 0001955589-26-000004 · wk-form4_1778702747.xml · derivative · entry 1

Poetting Sierk · CIK 0001955589 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,586

Underlying: Ordinary Shares · 12,586 shares

Expires 2036-05-12

F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

SEC source: 0002123971-26-000004 · wk-form4_1778702625.xml · derivative · entry 2

Jimenez Kylie · CIK 0002123971 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,391

Underlying: Ordinary Shares · 8,391 shares

Expires 2036-05-12

F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC source: 0002123971-26-000004 · wk-form4_1778702625.xml · derivative · entry 1

Jimenez Kylie · CIK 0002123971 · Chief People Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,488

Underlying: Ordinary Shares · 10,488 shares

Expires 2036-05-12

F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

SEC source: 0002118987-26-000002 · wk-form4_1778702527.xml · derivative · entry 2

Hanekamp Annemarie · CIK 0002118987 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,069

Underlying: Ordinary Shares · 10,069 shares

Expires 2036-05-12

F4 · derivative.exercise_date: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

F4 · derivative.underlying: Each performance share unit ("PSU") is the economic equivalent of one ordinary share of the Issuer and represents a right to receive, at the Issuer's option, one ordinary share, one ADS representing one ordinary share, or a cash payment or another form of settlement equal to the economic value thereof. PSUs vest annually in equal installments over four years commencing on the first anniversary of the grant date and become exercisable four years after the grant date, subject to the achievement of certain performance targets based on the market price of the Issuer's ordinary shares relative to the Nasdaq Biotechnology Index (or a comparable successor index) and the Reporting Person's continued service through each such date.

SEC source: 0002118987-26-000002 · wk-form4_1778702527.xml · derivative · entry 1

Hanekamp Annemarie · CIK 0002118987 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,586

Underlying: Ordinary Shares · 12,586 shares

Expires 2036-05-12

F1 · derivative.exercise_price: The exercise price of this option is EUR 89.38. Subject to adjustment such that the trading price of an American Depositary Share ("ADS") as of an exercise date does not exceed 800% of the grant date exercise price.

F2 · derivative.exercise_date: The option vests annually in equal installments over four years commencing on the first anniversary of the grant date and becomes exercisable four years after the grant date, subject to certain performance-based and other conditions.

F3 · derivative.underlying: The option may be settled in ordinary shares, ADSs and/or cash at the election of the supervisory board.

SEC source: 0001955589-26-000002 · wk-form4_1776974561.xml · nonDerivative · entry 1

Poetting Sierk · CIK 0001955589 · Chief Operating Officer

10b5-1 filing: Plan reported

Ownership: Indirect · See Footnote

Disclosed balance after: 399,387

F1 · ownership.nature: The ordinary shares are held by Tofino GmbH. The Reporting Person is the sole shareholder of Tofino GmbH and may be deemed to beneficially own the ordinary shares held by Tofino GmbH.